The first approved medical therapy is mifepristone, a nonselective GR antagonist, designated for adult patients with glucose intolerance or type 2 diabetes mellitus coupled with Cushing’s syndrome and are either ineligible for surgery or have undergone unsuccessful surgery [5]. Here, NR3C1 is linked to Cushing syndrome due to macronodular adrenal hyperplasia.